---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-004490"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T02:54:01.860182+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Neoleukin reports 2021 net loss of $60.7M, cash $142.5M; NL-201 interim data expected H2 2022

## Summary
- Net loss $60.7M in 2021 vs $33.3M in 2020; cash & equivalents $142.5M down from $192.6M; runway into H2 2023.
- Phase 1 interim data for NL-201 in solid tumors expected H2 2022; combination trial with pembrolizumab planned.
- R&D expenses $39.2M (up 61%), G&A $21.5M (up 25%) driven by clinical activities and personnel costs.
- Rohan Palekar (CEO of 89bio) appointed to board; Lewis Williams resigns; Drachman named PFO, Smith named PAO.

## SEC filing metadata
- accession: 0001628280-22-004490
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000162828022004490/0001628280-22-004490-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000162828022004490/nltx-20220225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-004490
- JSON: https://secwatch.observer/filing/0001628280-22-004490.json
- Plain text: https://secwatch.observer/filing/0001628280-22-004490.txt

## Key facts
- Executive change
  Lewis T. Williams resigned as Director at Neurogene Inc..
  - Action: resigned
  - Role: Director
  source text: the Board accepted the resignation of Lewis T. “Rusty” Williams as a member of the Board and its committees, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404644/000162828022004490/0001628280-22-004490-index.htm
- Executive change
  Rohan Palekar was appointed as Director at Neurogene Inc..
  - Action: appointed
  - Role: Director
  source text: the Board appointed Rohan Palekar as a Class III director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404644/000162828022004490/0001628280-22-004490-index.htm
- Executive change
  Sean Smith was appointed as Principal Accounting Officer at Neurogene Inc..
  - Action: appointed
  - Role: Principal Accounting Officer
  source text: the Board appointed Sean Smith, the Company’s VP, Finance and Controller, as the Company’s Principal Accounting Officer, effective on the Appointment Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404644/000162828022004490/0001628280-22-004490-index.htm
- Executive change
  Jonathan Drachman was appointed as Principal Financial Officer at Neurogene Inc..
  - Action: appointed
  - Role: Principal Financial Officer
  source text: the Board appointed Jonathan Drachman, the Company’s Chief Executive Officer, as the Company’s Principal Financial Officer, effective on March 2, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404644/000162828022004490/0001628280-22-004490-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.